NCT07077252尚未招募1 期
An Open Multi-center Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCTB39G in Adult Patients With Advanced Malignant Solid Tumours
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Dose-Limiting toxicity(DLT)
研究概览
简要总结
This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB39G as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.Voluntarily sign the informed consent form (ICF);
- •2.Male or female, ≥ 18 years and ≤ 70 years old;
- •3.Survival duration more than 3 months;
- •4.ECOG score ≤ 1 point;
- •5.histologically or cytologically confirmed diagnosis of advanced malignant solid tumour；
- •6.At least one measurable tumor lession according to RECIST v1.1;
- •7.Adequate organ and bone marrow function.
排除标准
- •1.Has participated in another clinical study within 4 weeks prior to the first dose;
- •2.Other malignancies diagnosed within 1 years prior to the enrollment;
- •Participants with brainstem, meningeal, spinal metastases, or compression; active central nervous system metastases;
- •4.NSCLC at high risk of bleeding; Obvious invasion of tumor into adjacent organs of esophageal lesions leads to high risk of bleeding or fistula,or participants after endotracheal stent implantation;
- •5.Participants with portal hypertension due to portal vein tumor thrombus at risk of bleeding;
- •6.Presence of pleural effusion, peritoneal effusion, or ascites;
- •7.Received chemotherapy, immunotherapy, biologic therapy, or other antitumor treatments within 4 weeks before enrollment
- •8.History of permanent discontinuation of immunotherapy due to immune-related toxicity or occurrence of ≥ Grade 3 irAEs;
- •9.Presence of any active autoimmune disease or a history of autoimmune disease with an expected recurrence;
- •10.History of severe allergies, severe drug allergies (including unapproved investigational drugs);
- •11.History of organ transplantation or stem cell transplantation;
- •12.Need for immunosuppressive drugs within 2 weeks prior to enrollment or anticipated during the study;
- •13.Pregnant or breastfeeding female.
研究组 & 干预措施
SCTB39G
Experimental
SCTB39G of different doses, IV
干预措施: SCTB39G (Drug)
结局指标
主要结局
Dose-Limiting toxicity(DLT)
时间窗: From Day 0 up to Day 21
Incidence of dose-limiting toxicities up to the Day 21 visit
Objective response rate (ORR)
时间窗: Up to 2 years
The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1
次要结局
- Disease control rate (DCR)(Up to 2 years)
- Progression-free survival (PFS)(Up to 2 years)
- Overall survival (OS)(Up to 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A phase I/IIa clinical study of BT-001 in the treatment of patients withmetastatic or advanced solid cancer.Phase I: Advanced or metastatic solid tumors including Non-Hodgkin Lymphoma (NHL) and preferably Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Smal Cell Lung Cancer Phase IIa: Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Smal Cell Lung CancerMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2020-000505-80-FRTRANSGENE48
进行中（未招募）
1 期
A phase I/IIa clinical study of BT-001 in the treatment of patients withmetastatic or advanced solid cancer.Phase I: Advanced or metastatic Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Smal Cell Lung Cancer Phase IIa: Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Smal Cell Lung CancerMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000505-80-BETRANSGENE258
招募中
1 期
A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid TumorOther Solid TumorsNSCLCNCT05332574Genor Biopharma Co., Ltd.120
尚未招募
Unknown
A phase II study of ABN401 in advanced solid tumors with c-MET gene aberration (Part of KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors [KOSMOS]-II)NeoplasmsKCT0008450Yonsei University Health System, Severance Hospital20
终止
1 期
A Study of SGN-STNV in Advanced Solid TumorsCarcinoma, Non-Small Cell LungHER2 Negative Breast NeoplasmsOvarian NeoplasmsUterine Cervical NeoplasmsEndometrial NeoplasmsEsophageal NeoplasmsGastroesophageal Junction CarcinomaStomach NeoplasmsPseudomyxoma PeritoneiExocrine Pancreatic AdenocarcinomaAppendiceal AdenocarcinomaColorectal NeoplasmsNCT04665921Seagen Inc.111